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Abstract Advanced glycation end products (AGEs)
have a pivotal role in atherosclerosis. We evaluated
skin autoﬂuorescence (SAF), a non-invasive measure-
ment of tissue AGE accumulation, in patients with
carotid artery stenosis with and without coexisting
peripheral artery occlusive disease (PAOD). SAF was
measured using the AGE Reader
TM in 56 patients with
carotid artery stenosis and in 56 age- and sex-matched
healthy controls without diabetes, renal dysfunction or
known atherosclerotic disease. SAF was higher in
patients with carotid artery stenosis compared to the
control group: mean 2.81versus 2.46 (P = 0.002), but
especially in the younger age group of 50–60 years
old: mean 2.82 versus 1.94 (P = 0.000). Patients with
carotid artery stenosis and PAOD proved to have an
even higher SAF than patients with carotid artery
stenosis only: mean 3.28 versus 2.66 (P = 0.003).
Backward linear regression analysis showed that age,
smoking, diabetes mellitus, renal function and the
presence of PAOD were the determinants of SAF, but
carotid artery stenosis was not. SAF is increased in
patients with carotid artery stenosis and PAOD. The
univariate and multivariate associations of SAF with
age, smoking, diabetes, renal insufﬁciency and PAOD
suggest that increased SAF can be seen as an indicator
of widespread atherosclerosis.
Keywords Carotid artery stenosis  Peripheral
vascular disease  Advanced glycation end products 
Skin autoﬂuorescence
Introduction
Advanced glycation end products (AGEs) accumulate
in long lived tissue during lifetime, which is regarded
as a process of normal ageing. AGE accumulation
results from a combination of hyperglycaemia,
hyperlipaemia, oxidative/carbonyl stress and also
decreased renal clearance of AGE precursors. Accel-
erated AGE accumulation is therefore, seen in
diabetes mellitus and renal failure and contributes
to long term complications and mortality [1–3] AGEs
also play a major pathogenetic role in atherosclerosis
[4–7]. Cross linking of AGEs with collagen and
elastin within the vascular wall contributes to arterial
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DOI 10.1007/s10554-011-9805-6stiffness [1, 5, 6]. AGEs also alter the extracellular
matrix and promote atheroma formation [6–8]. Fur-
thermore, activation of cell membrane receptors
including the receptor for AGE (RAGE) leads to
activation of several oxidative and inﬂammatory
pathways [1, 7, 8]. This cascade leads to endothelial
dysfunction, vascular inﬂammation and production of
reactive oxygen species [1]. These mechanisms
accelerate the formation of atherosclerosis [1].
Finally, AGE accumulation and overexpression of
RAGE within the plaque may promote plaque
instability [6].
Accumulation of AGEs in tissue can be assessed
through illumination of the skin, a technique named
skin autoﬂuorescence (SAF), which has previously
been validated by simultaneous measurements of
SAF and contents of speciﬁc AGE assessments in
skin biopsies [9–11]. Although the ﬂuorescent char-
acteristics in this method are not speciﬁc for ﬂuores-
cent AGE, multiple validation studies have shown
convincingly and consistently that SAF has a strong
correlation with speciﬁc AGE content in skin biopsies
[9–11]. The correlation between SAF with the
ﬂuorescent AGE pentosidine is very high: r = 0.87.
Surprisingly, not only ﬂuorescent AGE (pentosidine)
but also non ﬂuorescent AGE (N-carboxymethyl-
lysine (CML) and N-carboxyethyl-lysine (CEL)) in
the skin biopsies showed great correlation with SAF.
Skin AGE content explained the major part of the
variance (up to 76%) in the SAF signal in a pooled
analysis of three validation studies [10]. We earlier
reported increased SAF in several groups of patients
with increased AGEs formation such as diabetes
mellitus [3, 12], decreased clearance of AGEs such as
renal failure [13] and overt atherosclerotic disease
such as patients with stable coronary artery disease
[14]. Earlier studies have already demonstrated an
elevated serum level of AGEs in patients with carotid
disease; a positive association between intima media
thickness (IMT) and serum levels of AGEs were
found in population with renal insufﬁciency starting
dialysis [15]. Baumann et al. showed that the AGE
N-epsilon-carboxymethyllysine (CML) is present in
the subendothelial space of atherosclerotic human
carotid artery material of normoglycaemic subjects
with a mean age of 50 years [16]. However, the level
of SAF as a measurement of increased tissue
accumulation of AGEs rather than plasma AGEs
level has not yet been studied in patients with carotid
artery stenosis. Therefore, the present study evaluates
SAF in patients with atherosclerotic carotid artery
stenosis with or without coexisting peripheral arterial
disease. The possible value of SAF as a risk indicator
in this speciﬁc cohort of patients is further discussed.
Materials and methods
Subjects
Between October 2007 and May 2008 56 consecutive
patients with carotid artery stenosis admitted to the
outpatient clinic of the Department of Surgery
(Division of Vascular Surgery) in our tertiary referral
hospital participated in the study after informed
consent was obtained. The degree of stenosis and
basic morphologic features of the plaque were
evaluated by duplex ultrasound. Duplex ultrasound
was performed in the clinical setting as part of
standard medical care. This was performed by one
observer, a specialized sonographer of the department
of vascular surgery of our university hospital. Inclu-
sion criteria were the presence of a symptomatic
stenosis of 70–99% (or less in case of ulcerative soft
plaques) or an asymptomatic stenosis of 80–99%.
There were no exclusion criteria. 56 age- and sex-
matched controls were recruited at the outpatient
clinic of the Department of Anaesthesiology for
preoperative evaluation prior to an elective non-
cardiovascular related surgical procedure. Control
patients were eligible if they did not have a history of
diabetes, cardiovascular disease or renal disease.
Carotid ultrasound was not performed in the control
group.
Study protocol
In both groups, classical cardiovascular risk factors as
well as other factors that are known to inﬂuence AGE
accumulation were inventoried: body mass index,
smoking status, diabetes mellitus, hypertension
(deﬁned as a blood pressure of more than 140/90
mmHg or the use of antihypertensive medication),
hypercholesterolemia (depicted by the use of statins),
renal function and the presence of coronary artery
disease and peripheral artery occlusive disease
(PAOD). SAF was measured in carotid artery stenosis
and control patients.
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SAF was measured with the AGE Reader
TM (Diag-
nOptics Technologies BV, Groningen, the Nether-
lands). The AGE Reader
TM is a desk-top device that
uses the characteristic ﬂuorescent properties of some
AGEs to estimate the level of AGE accumulation in
the skin. Technical details of this non-invasive device
concerning the optical technique have been described
more extensively elsewhere [10]. In short, the AGE
Reader illuminates a skin surface of 4 cm
2 guarded
against surrounding light with an excitation light
source with a peak excitation of 370 nm. Emission
light (ﬂuorescence in the wavelength of 420–600 nm)
and reﬂected excitation light (with a wavelength of
300–420 nm) from the skin is measured with a
spectrometer. SAF is calculated as the ratio between
the emission light and reﬂected excitation light,
multiplied by 100 and expressed in arbitrary units.
In the current series of experiments, the right
forearm was positioned on top of the device. The
right forearm is the standard measuring site for SAF
as it is the most practical site and autoﬂuorescence is
believed to be uniformly distributed throughout the
body. A series of three consecutive measurements
was carried out, which took less than a minute time.
The mean SAF of three consecutive measurements
was calculated and used in the analyses. An earlier
validation study showed an intra individual Altman
error percentage of 5.03% with SAF measurements
taken over 1 single day and an Altman error
percentage of 5.87% over seasonal variation [10].
Between subjects, SAF has a standard deviation of
approximately 0.5 AU [17]. SAF shows a linear
increase with age of 0.023 AU per year for subjects
up to 70 years [17]. Gender had no inﬂuence on SAF
in non-smokers. In smokers, SAF was 0.2 AU higher
in females [17]. The SAF measurement with the AGE
reader is independent of skin colour when reﬂectance
values are above 12% as was the case in all of the
study participants [10]. Measurements were per-
formed in fasting state as previous studies showed a
postprandial rise up to 12% [18, 19].
Statistical analysis
Power analysis was based on the reference values for
SAF provided by Koetsier et al. [17]. Using a mean
SAF of 2.5 AU with a SD of 0.55 AU, 56 patients and
56 controls were needed to detect a difference of at
least 0.3 AU (=12%) with a power of 80% and a
P-value\0.05. Data were prospectively gathered in a
database (SPSS 15-0, SPSS Inc, Chicago, Illinois,
USA). Distribution of variables was tested by the
Kolmorgorov-Smirnov test. All parameters showed a
normal distribution. Descriptive statistics are there-
fore, presented as mean with standard deviation or as
number of patients. For comparison between contin-
uous variables the t-test was used. For categorical
variables the Fisher exact test was used. Correlations
between variables were analysed by Pearson’s corre-
lation. Subsequently, backward linear regression
analysis was performed to determine the parameters
that independently inﬂuenced SAF. A P-value less
than 0.05 was regarded as statistically signiﬁcant.
Results
Subject characteristics
Patient characteristics are summarized in Table 1.
The mean age of both groups was approximately
69 years. All patients were Caucasian and thirty-
seven patients (66%) were male in both groups. As
expected, the presence of traditional cardiovascular
risk factors as well as established coronary artery or
peripheral artery occlusive disease (PAOD) was
signiﬁcantly higher in the patients with carotid artery
stenosis. Twenty ﬁve patients with carotid artery
stenosis were current smokers compared to 9 in the
control group. Mean BMI was not different between
the groups, both approximately 27.5 kg/m
2. Twelve
patients (21%) had diabetes mellitus and three of
them used insulin therapy. Mean blood pressure was
153/80 mmHg in the patients with carotid artery
disease and 156/84 mmHg in the control group.
Diastolic blood pressure was signiﬁcantly higher in
the control group. Nearly all patients with carotid
artery stenosis had hypertension (n = 54) and nearly
half of them used more than two antihypertensive
agents. Signiﬁcantly fewer subjects in the control
group had hypertension (n = 43) but only 18 of these
hypertensive controls received antihypertensive med-
ication. Statins were used by 49 patients with carotid
artery stenosis (87.5%), while only one subject in the
control group was on statin therapy. All patients with
carotid artery stenosis used either antiplatelet therapy
Int J Cardiovasc Imaging (2012) 28:431–438 433
123(n = 50) or an oral vitamin K inhibitor (n = 6).
Mean serum creatinin was 90 in the patients with
carotid artery stenosis and 96 umol/l in the control
group. Nearly half of the patients with carotid artery
stenosis also had either coronary artery disease or
peripheral artery occlusive disease (n = 26). Of the
56 patients with carotid artery disease, 14 had
coexisting PAOD and 17 coexisting coronary artery
disease. As a consequence of the exclusion criteria,
none of the control group patients had atherosclerotic
manifestations.
Skin autoﬂuorescence
Overall, SAF was signiﬁcantly higher in the patients
with carotid artery stenosis (mean SAF 2.81) com-
pared to the control group (mean SAF 2.46)
(Table 2). After stratiﬁcation for age, the difference
in SAF was primarily observed in the age category of
50–60 years: a mean SAF of 2.82 in the carotid artery
stenosis patients versus a mean SAF of 1.94 in the
controls. (Table 2). After exclusion of patients with
diabetes mellitus the differences in SAF remained
signiﬁcant in the total group with carotid artery
stenosis as well as in the age subgroup of 50–60 years
old. Figure 1 shows that the control group exhibits
the natural increase of SAF with advancing age
(r = 0.52, P\0.001). In the patient group with
carotid artery stenosis, the relationship between SAF
and age has disappeared as younger patients already
have a high SAF (r = 0.094, P = 0.49).
Within the carotid artery stenosis group, the degree
of stenosis did not inﬂuence SAF (P = 0.71). Also,
no difference in SAF was found between the
asymptomatic and symptomatic patients with carotid
artery stenosis (P = 0.21).
PAOD proved to be strongly associated with a
high SAF. Patients with PAOD had a higher SAF
than patients without peripheral arterial occlusive
disease. When comparing SAF of patients with
carotid artery stenosis and PAOD to SAF in the
control group, SAF was 3.28 (0.66) versus 2.46 (0.57)
with a P value of 0.000 (Table 2). Even within the
group of carotid artery stenosis, SAF was signiﬁ-
cantly higher when there was coexisting PAOD.
Subjects with both carotid artery stenosis and PAOD
had a SAF of 3.28 (0.66) versus 2.66 (0.53) for
subjects with only carotid artery stenosis without
coexisting PAOD. When excluding patients with
PAOD, the difference in SAF between the patients
with carotid artery stenosis and controls was limited
and even lost statistical signiﬁcance: SAF was 2.66
Table 1 Baseline
characteristics presented as
mean (standard deviation),
median (interquartile range)
or as number of patients (%)
Characteristic Carotid artery stenosis Control subjects P
N5 6 5 6
Age (years) 69.0 (7.8) 68.9 (7.9) 0.96
Male sex 37 (66%) 37 (66%) 1.0
Current smoker 25 (45%) 9 (16%) 0.002
BMI (kg/m2) 27.2 (4.9) 27.8 (3.9) 0.49
Diabetes mellitus 12 (21%) 0 0.001
Diabetes mellitus requiring insulin 3 (5%) 0 0.24
Systolic blood pressure 153 (22) 156 (22) 0.47
Diastolic blood pressure 80 (74–89) 84 (80–89) 0.016
Hypertension ([140/90 mmHg/med) 54 (96%) 43 (77%) 0.004
Antihypertensive medication 52 (93%) 18 (32%) \0.001
[2 antihypertensive agents 22 (39%) 2 (4%) \0.001
Statin therapy 49 (88%) 1 (2%) \0.001
Serum creatinine 90.1 (34.5) 95.6 (15.7) 0.28
Renal clearance (MDRD) 84 (37) 73 (16.7) 0.050
Anti platelet therapy 50 (89%) 0 \0.001
Coronary artery disease 17 (30%) 0 \0.001
PAOD 14 (25%) 0 \0.001
Coronary artery disease and/or PAOD 26 (46%) 0 \0.001
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(Table 2). Between the patients with carotid artery
stenosis with and without coexisting PAOD no
statistical differences between baseline characteristics
could be found. Unlike PAOD, the presence of
coexisting coronary artery disease did not result in a
higher SAF. Subjects with carotid artery stenosis and
also coronary artery disease had a SAF of 2.82 (0.69)
while this was 2.81 (0.46) for patients with carotid
artery disease without coexisting coronary disease.
Correlations and univariate analysis
Univariate analysis and correlations were performed
in the combined total group to determine the
relationship of different parameters with SAF. A
signiﬁcant correlation of SAF was found with age
(r = 0.29, P\0.01) and with renal function (r =
0.24, P = 0.01). A signiﬁcantly higher SAF was
found in current smokers (mean 3.01 versus mean
2.47, P\0.001), diabetes mellitus (mean 3.03 versus
2.59, P = 0.02), those using statins (mean 2.87
versus 2.44, P\0.001), those with hypertension
(mean 2.73 versus 2.48, P = 0.04) and those with
coexistence of PAOD (mean 3.28 versus 2.46,
P\0.001). Gender, BMI, hypertension and coronary
artery disease had no signiﬁcant inﬂuence in univar-
iate analysis.
Backward linear regression analysis
Backward linear regression analysis was performed
in the combined total group to determine the param-
eters that independently contributed to SAF. The
results are shown in Table 3. Age, smoking, diabetes
mellitus, renal function and presence of PAOD were
the signiﬁcant determinants of SAF. In contrast to the
results of univariate analysis the presence of carotid
artery disease did not contribute signiﬁcantly with a ß
Table 2 Skin
autoﬂuorescence in patients
with carotid artery stenosis
compared with healthy
controls
Analysis of different age
groups. Peripheral artery
occlusive disease and
coronary artery disease are
denoted by, respectively
PAOD and CAD. Statistical
signiﬁcance is notated by*
Skin autoﬂuorescence Carotid artery
stenosis
N Control subjects NP -value
Total group 2.81 (0.62) 56 2.46 (0.57) 56 0.002*
Total group without diabetes 2.75 (0.64) 44 2.46 (0.57) 56 0.016*
Total group with PAOD 3.28 (0.66) 14 2.46 (0.57) 56 0.000*
Total group without PAOD 2.66 (0.53) 42 2.46 (0.57) 56 0.084
Total group with CAD 2.82 (0.46) 17 2.46 (0.57) 56 0.021*
Total group without CAD 2.81 (0.69) 39 2.46 (0.57) 56 0.008*
50–60 years 2.82 (0.54) 8 1.94 (0.30) 10 0.000*
50–60 years without diabetes 2.79 (0.37) 5 1.94 (0.30) 10 0.000*
60–70 years 2.73 (0.58) 23 2.40 (0.54) 21 0.06
70–80 years 2.90 (0.71) 21 2.73 (0.55) 24 0.37
[80 years 2.83 (0.74) 4 2.19 (n = 1) 1 0.49
Fig. 1 Scatter plot showing SAF in relation to age in patients
with carotid artery stenosis and controls. Circles denote control
subjects, triangles patients with carotid artery stenosis, stars
patients with carotid artery stenosis and coexisting PAOD.
Trend lines are shown for controls (dotted line) and carotid
artery stenosis (continuous line). The control group exhibits the
natural increase of SAF with advancing age. In the patient
group with carotid artery stenosis, the relationship between
SAF and age has disappeared. Patients with carotid artery
stenosis and coexisting PAOD show a higher SAF than the
control subjects and the patients with carotid artery disease
only
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not contribute with a ß of 0.038 (P = 0.48).
Discussion
In the current study we showed that SAF is signif-
icantly elevated in patients with carotid artery
stenosis and PAOD compared to controls. Two
ﬁndings were especially remarkable.
First, PAOD proved to be an important determi-
nant of SAF. High SAF values were especially found
in the group with carotid artery disease and coexis-
ting PAOD. Even within the group of carotid artery
disease, SAF was signiﬁcantly higher when there was
coexisting PAOD with a SAF of 3.36 versus 2.64
(P = 0.003). This could not be explained by differ-
ences in baseline characteristics between the patients
with carotid artery stenosis with or without PAOD.
Also in linear regression analysis, PAOD proved to
be a strong determinant of SAF, even more so then
diabetes. This ﬁnding is interesting and warrants
further research. It suggests that SAF should primar-
ily be seen as an indicator of widespread atheroscle-
rotic disease. Currently, a study analysing SAF in
patients with primary peripheral artery disease has
been initiated.
The second remarkable ﬁnding was that SAF was
speciﬁcally elevated for patients in the age group
50–60 years. Furthermore, the relation between age
and SAF, as normally seen, was present in the control
group but absent in the patients with carotid artery
stenosis.
The marked elevation of SAF levels in carotid
artery stenosis was demonstrated in non-diabetic
patients as well as in diabetics. A high SAF in
diabetes mellitus may therefore, be regarded as an
indicator of widespread atherosclerotic disease and
not only a manifestation of diabetes mellitus per se.
Mulder et al. previously reported similar ﬁndings in a
cohort with stable coronary artery disease [14]. SAF
was signiﬁcantly increased in stable coronary artery
disease compared with controls, irrespective of
diabetes, current smoking and renal function. Earlier
studies in patients with diabetes mellitus also showed
that SAF is manifestly increased in these patients.
The level of AGE accumulation correlated with the
duration and the grade of complications of diabetes
[2, 3, 20].
Univariate and multivariate analysis of associa-
tions with SAF in the present study supports this
interpretation in our study group of patients with
carotid artery stenosis. SAF was univariately associ-
ated with age, smoking, diabetes mellitus, renal
dysfunction, dyslipidaemia and the presence of
carotid artery disease and peripheral arterial occlu-
sive disease which is in concordance with earlier
studies [2, 3, 10, 13] Multivariately, SAF was
determined by age, smoking, diabetes mellitus, renal
dysfunction and peripheral arterial occlusive disease.
Therefore, again, increased SAF may rather be
regarded as an indicator of widespread atherosclerotic
disease than as a speciﬁc identiﬁer of carotid
atherosclerotic disease.
This study however, has several limitations. At
baseline, despite matching for sex and age in the
control group, there were differences between the
patient and control groups including presence of
diabetes, smoking behaviour, hypertension, use of
antihypertensive medication and use of statins. This
may be considered a source of confounding. How-
ever, it does represent the expected increased pres-
ence of risk factors for cardiovascular disease in
patients with carotid artery stenosis compared to
healthy people.
In the control group asymptomatic atherosclerosis
may have existed as no carotid ultrasound or other
vascular tests were performed in the control group. If
asymptomatic atherosclerosis was present in the
control group this would result in an underestimation
of the difference between the control group and
patient group. The differences we found between the
Table 3 Results of backward linear regression analysis
Included parameter ßeta P-value
Age 0.24 0.02
Current smoker 0.36 0.00
Diabetes mellitus 0.21 0.01
EGFR (MDRD) 0.20 0.05
Peripheral artery occlusive disease 0.29 0.00
The remaining signiﬁcant predictors of skin autoﬂuorescence
are shown. Carotid artery disease, coronary artery disease, sex,
BMI, hypertension and use of statin medication did not
signiﬁcantly inﬂuenced skin autoﬂuorescence. Carotid artery
disease and coronary artery disease both did not contribute
signiﬁcantly with, respectively a ß of 0.074 (P = 0.83) and
0.038 (P = 0.48)
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123control group and the group with atherosclerotic
carotid stenosis and peripheral artery disease there-
fore, would be even greater in a better selected
control group.
Our study is also limited by the small number of
patients. The fact that backward linear regression did
not show carotid artery disease or coronary artery
disease to be independent determinants of SAF may
therefore, be caused by the lack of power. Mulder
et al. has earlier shown that SAF indeed is elevated in
stable coronary disease [14]. A large study evaluating
the relationship between SAF en intima media
thickness is currently being executed to further
clarify this issue. What may be the use of the present
results? The correlation of SAF with traditional
cardiovascular risk factors, the presence of diabetes,
renal insufﬁciency and peripheral arterial occlusive
disease could indicate that SAF may be an indicator
of high cardiovascular risk patients. Moreover, since
SAF represents end organ damage it may predict
morbidity and mortality more than the classical risk
factors for atherosclerosis separately. For patients
with type 2 diabetes this has already been established
since SAF added prognostic information to the
UKPDS risk calculator in predicting mortality [21].
Strong predictive results of SAF for cardiovascular
mortality were also seen in patients with renal failure
[22]. The same may be true for patients with carotid
artery stenosis and peripheral artery disease. Pro-
spective follow-up studies are necessary to elucidate
this. Moreover, spectroscopy techniques show prom-
ising results for imaging vulnerable plaques and the
near future will tell whether they really shine light on
unstable cardiovascular disease.
In conclusion, skin autoﬂuorescence is increased in
patients with carotid artery stenosis and PAOD com-
paredtohealthycontrols.SAFisespeciallyelevatedin
the age group of 50–60 years, suggesting an increased
accumulation of tissue AGEs in these patients. The
univariate and multivariate associations of SAF with
age, smoking, diabetes mellitus, presence of renal
insufﬁciency and peripheral arterial occlusive disease
suggestthatincreasedSAFshouldprimarilybeseenas
an indicator of widespread atherosclerotic disease.
These associations further underscore the important
roleofAGEsinthepathophysiologyofatherosclerotic
disease. SAF might therefore, be an indicator of an
overall high burden of widespread atherosclerosis as a
consequence of AGE accumulation. Future research
should investigate the use of SAF as a superior
predictor of cardiovascular events in this population.
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